Published in Br J Clin Pharmacol on January 01, 1988
Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med (2014) 2.45
Perioperative hypertension management. Vasc Health Risk Manag (2008) 1.13
Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene (2015) 0.83
Pharmacokinetics And Pharmacodynamics Of Fenoldopam Mesylate For Blood Pressure Control In Pediatric Patients. BMC Anesthesiol (2008) 0.80
Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs. J Vet Pharmacol Ther (2011) 0.78
PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med (1984) 2.09
Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther (1982) 1.69
A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther (1983) 1.27
The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol (1986) 1.04
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther (1987) 1.03
Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation (1984) 1.01
Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest (1984) 0.95
Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr (1984) 0.91
Classification of human colorectal adenocarcinoma cell lines. Cancer Res (1976) 7.00
Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev (1972) 5.07
Statins do more than just lower cholesterol. Lancet (1996) 4.39
Management of hyperglycemic crises in patients with diabetes. Diabetes Care (2001) 4.04
Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med (1983) 3.27
Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther (1966) 2.52
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol (1999) 2.18
Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther (1969) 2.11
Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J Biol Chem (2001) 2.02
Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med (1974) 1.89
Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology (1997) 1.87
Dopamine in the treatment of hypotension and shock. N Engl J Med (1966) 1.77
Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet (1982) 1.73
Role of nifedipine in treatment of hypertension. Br Med J (Clin Res Ed) (1983) 1.70
The potential role of dopamine in the treatment of shock. Prog Cardiovasc Dis (1969) 1.70
Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med (1986) 1.53
Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med (1994) 1.53
The development of the Dallas Pain Questionnaire. An assessment of the impact of spinal pain on behavior. Spine (Phila Pa 1976) (1989) 1.49
New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex. J Natl Cancer Inst (1973) 1.49
CLCN5 mutation Ser244Leu is associated with X-linked renal failure without X-linked recessive hypophosphatemic rickets. Kidney Int (1998) 1.47
STUDIES ON DIGITALIS. IV. OBSERVATIONS IN MAN ON THE EFFECTS OF DIGITALIS PREPARATIONS ON THE CONTRACTILITY OF THE NON-FAILING HEART AND ON TOTAL VASCULAR RESISTANCE. J Clin Invest (1961) 1.45
A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol (1978) 1.41
Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis (1977) 1.32
The use of quaternary narcotic antagonists in opiate research. Neuropharmacology (1985) 1.27
Effects of dopamine on isolated canine coronary arteries. Cardiovasc Res (1975) 1.23
Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain (2008) 1.19
Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther (1984) 1.17
Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry (2002) 1.16
The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells. Mol Cell Biol (1994) 1.15
Comparing claims data and self-reported data with the medical record for Pap smear rates. Eval Health Prof (1997) 1.15
A hemodynamic comparison of dopamine and isoproterenol in patients in shock. Circulation (1969) 1.14
Effects of dopamine on renal function and hemodynamics in the dog. J Pharmacol Exp Ther (1967) 1.12
Comparison of two noninvasive screening tests for renovascular hypertension. Arch Intern Med (1993) 1.12
Use of sympathomimetic amines in heart failure. Am J Cardiol (1968) 1.11
Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia. JAMA (1974) 1.11
An investigation of the structural requirements for dopamine-like renal vasodilation: phenylethylamines and apomorphine. J Pharmacol Exp Ther (1968) 1.11
Atopy, immunological changes, and respiratory function in bronchiectasis. Thorax (1984) 1.10
The effects of nifedipine and hydralazine induced hypotension on sympathetic activity. Eur J Clin Pharmacol (1982) 1.10
Attenuation of dopamine-induced renal vasodilation in the dog by phenothiazines. Eur J Pharmacol (1971) 1.09
Mapping of the novel protein kinase catalytic domain of Dictyostelium myosin II heavy chain kinase A. J Biol Chem (1997) 1.08
Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol (1983) 1.07
The pharmacokinetics and metabolism of cimetidine in neonates. Dev Pharmacol Ther (1984) 1.03
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther (1987) 1.03
Dopamine receptors: applications in clinical cardiology. Circulation (1985) 1.03
Regulation of intracellular calcium by cell pH in vascular smooth muscle cells. Am J Physiol (1989) 1.00
Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study. Ann N Y Acad Sci (2007) 1.00
Dopamine-like renal and mesenteric vasodilation caused by apomorphine 6-propylnorapomorphine and 2-amino-6, 7-dihydroxy-1,2,3,4-tetrahydronaphthalene. Nature (1976) 1.00
Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol (1979) 1.00
Recent advances in the pharmacology of catecholamines. Intensive Care Med (1977) 1.00
Histofluorescence techniques provide evidence for dopamine-containing neuronal elements in canine kidney. Science (1979) 0.99
Iridectomy in primary angle-closure glaucoma. Classification and differential diagnosis of glaucoma associated with narrowness of the angle. Arch Ophthalmol (1974) 0.99
Mental confusion in a patient treated with metronidazole--a concentration-related effect? Pharmacotherapy (1983) 0.98
Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa. N Engl J Med (1971) 0.97
Diurnal blood pressure variation and cardiac mass in American blacks and whites and South African blacks. Am J Hypertens (1992) 0.97
Physical activity level is an independent predictor of the diurnal variation in blood pressure. J Hypertens (2000) 0.96
Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins (1984) 0.96
Liquid-chromatographic determination of cimetidine, its known metabolites, and creatinine in serum and urine. Clin Chem (1981) 0.95
Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations. Circulation (1974) 0.94
Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res (1970) 0.93
Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine. Clin Pharmacol Ther (1983) 0.93
Ambulatory blood pressure monitoring: which arm? J Hum Hypertens (2000) 0.93
Regional variation in the alpha-adrenergic receptors in the canine resistance vessels. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.92
Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol (1982) 0.92
The treatment of cardiogenic shock. VI. The search for an ideal drug. Am Heart J (1968) 0.91
Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clin Pharmacol Ther (1991) 0.91
Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr (1984) 0.91
Characteristics of the vascular dopamine receptor: comparison with other receptors. Fed Proc (1978) 0.91
Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390. Am J Physiol (1985) 0.90
Characterization by cyproheptadine of the dopamine-induced contraction in canine isolated arteries. J Pharmacol Exp Ther (1975) 0.90
Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Am J Nephrol (1999) 0.89
Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am J Med (1984) 0.89
Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients. Circulation (1995) 0.88
Distribution, fate and risk assessment of antibiotics in sewage treatment plants in Hong Kong, South China. Environ Int (2011) 0.88
HPLC determination of D and L moxalactam in human serum and urine. J Pharm Sci (1982) 0.88
Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation (1987) 0.88
Nocturnal blood pressure dipping: a consequence of diurnal physical activity blipping? Am J Hypertens (2000) 0.88
Detection of beta-blocker use in people with asthma. Ann Allergy (1992) 0.87
Propylbutyldopamine: hemodynamic effects in conscious dogs, normal human volunteers and patients with heart failure. Circulation (1983) 0.87
Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation (1986) 0.87
Changes in blood pressure and plasma catecholamines caused by tyramine and cold exposure. J Cardiovasc Pharmacol (1984) 0.87
Dopamine induced relaxation of isolated canine renal, mesenteric, and femoral arteries contracted with prostaglandin F2-alpha. Circ Res (1975) 0.87
The influence of physical activity on the variability of ambulatory blood pressure. Am J Hypertens (2000) 0.87
Penetration characteristics of trimethoprim-sulfamethoxazole in middle ear fluid of patients with chronic serous otitis media. J Pediatr (1980) 0.86
Effects of levodopa on systolic preejection period, blood pressure, and heart rate during acute and chronic treatment of Parkinson's disease. Circulation (1972) 0.86
Ethnic differences in circadian hemodynamic profile. Am J Hypertens (1994) 0.86
Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390. Hypertension (1984) 0.86
The dopamine vascular receptor. Biochem Pharmacol (1975) 0.86
Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog. J Pharmacol Exp Ther (1987) 0.86
Nifedipine and alpha adrenoceptor antagonism. Clin Pharmacol Ther (1984) 0.86
Cardiovascular effects of levodopa. JAMA (1971) 0.86
Cardiovascular effects of (--)-cathinone in the anaesthetized dog: comparison with (+)-amphetamine. J Pharm Pharmacol (1982) 0.86
Insidious and prolonged antagonism of guanethidine by amitriptyline. JAMA (1970) 0.85
Identification and characterization of a nerve growth factor-stimulated mitogen-activated protein kinase activator in PC12 cells. J Biol Chem (1993) 0.85
Failure of cimetidine in Zollinger-Ellison syndrome. Dig Dis Sci (1983) 0.85
Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica (1989) 0.85
Relative activities of SCH 23390 and its analogs in three tests for D1/DA1 dopamine receptor antagonism. Eur J Pharmacol (1986) 0.85